Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study-Reference-Cited by-同舟云学术

Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study

Published:2023-03 Issue:3 Volume:10 Page:e168-e177
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Négrier Claude,Mahlangu Johnny,Lehle Michaela,Chowdary Pratima,Catalani Olivier,Bernardi Ronald J,Jiménez-Yuste Víctor,Beckermann Benjamin M,Schmitt Christophe,Ventriglia Giuliana,Windyga Jerzy,d'Oiron Roseline,Moorehead Paul,Koparkar Sunita,Teodoro Vanda,Shapiro Amy D,Oldenburg Johannes,Hermans Cedric

Funder

Hospices Civils de Lyon

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Hematology

Reference35 articles.

1. WFH guidelines for the management of hemophilia, 3rd edn;Srivastava;Haemophilia,2020

2. Definitions in hemophilia: communication from the SSC of the ISTH;Blanchette;J Thromb Haemost,2014

3. Arthropathy in patients with moderate hemophilia a: a systematic review of the literature;Di Minno;Semin Thromb Hemost,2013

4. The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B;Soucie;Blood Adv,2018

5. Joint status of patients with nonsevere hemophilia A;Zwagemaker;J Thromb Haemost,2022

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab as a Promising Form of Therapy for Type A Hemophilia - AReview of Current Knowledge from Clinical Trials;Current Protein & Peptide Science;2024-11

2. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies;Expert Review of Hematology;2024-09-12

3. Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab;Blood;2024-09-12

4. The Development and Validation of the Comprehensive Assessment Tool for Challenges in Hemophilia (CATCH) 2.0;2024-07-17

5. Reduced doses of emicizumab achieve good efficacy: Results from a national‐wide multicentre real‐world study in China;Haemophilia;2024-06-09